

CAPTURING OSTEOPOROSIS PRESCRIPTIONS VIA SUPPLEMENTAL DATA

The Osteoporosis Management measure is the percentage of women ages 67–85 who have suffered a fracture during the measurement year. Compliance for the measure is based on women who have had either a bone mineral density (BMD) test or a prescription for a drug to treat or prevent osteoporosis in the six months after the fracture. Additional information on the specifics of the measure can be found within the Highmark Medicare Advantage Primary Care Incentive Program Measure Guide.

Patients who were taking a medication to treat osteoporosis or received a BMD test during the twelve months prior to the fracture can be excluded from this measure.

If your patient is actively taking an osteoporosis medication and has used their Highmark benefits at the dispensing pharmacy, they will be considered compliant for the measure due to a claim being generated. **If your patient is not using their Highmark insurance, documentation should be submitted via the Clinical Quality Feedback Loop to receive credit.**

Use the Clinical Quality Feedback function if your patient was taking one of the medications below in the 12 months prior to the fracture or within 6 months after the fracture, but received the medication via:

- VA
- Patient Assistance Programs
- Samples
- Retail Pharmacy Programs (such as \$4 generics)
- Pharmacy Discount Cards
- Paying Cash

Medications*

Abaloparatide (Tymlos)	Denosumab (Xgeva)	Romosozumab-aqqg (Evenity)
Alendronate (Binosto)	Ibandronate (Boniva)	Teriparatide (Forteo)
Alendronate (Fosamax)	Raloxifene (Evista)	Zoledronic acid (Reclast)
Alendronate-Cholecalciferol (Fosamax Plus D)	Risedronate (Actonel)	Zoledronic acid (Zometa)
Denosumab (Prolia)	Risedronate (Atelvia)	

The Clinical Quality Feedback function is accessible via NaviNet[®]. Documentation that the patient received an osteoporosis medication must include the following:

- Generic name of the medication
- Strength/dose
- Route of administration
- Date the patient received the medication
- Quantity (required for samples only)
- Lot number (required for samples only)
- Expiration date (required for samples only)

For additional information on how to submit supplemental data, including how to submit BMD tests, please refer to the **Clinical Quality Feedback Supplemental Guide** located on the Provider Resource Center or the Quality Blue User Interface.

This information is issued on behalf of Highmark Blue Shield and its affiliated Blue companies, which are independent licensees of the Blue Cross Blue Shield Association. Highmark Inc. d/b/a Highmark Blue Shield and certain of its affiliated Blue companies serve Blue Shield members in 21 counties in central Pennsylvania and 13 counties in northeastern New York. As a partner in joint operating agreements, Highmark Blue Shield also provides services in conjunction with a separate health plan in southeastern Pennsylvania. Highmark Inc. or certain of its affiliated Blue companies also serve Blue Cross Blue Shield members in 29 counties in western Pennsylvania, 13 counties in northeastern Pennsylvania, the state of West Virginia plus Washington County, Ohio, the state of Delaware, and 8 counties in western New York. All references to Highmark in this document are references to Highmark Inc. d/b/a Highmark Blue Shield and/or to one or more of its affiliated Blue companies.

NaviNet is a registered trademark of NaviNet Inc., which is an independent company that provides secure, web-based portal between providers and health insurance companies.